Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ralmitaront in Patients With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
NCT03669640Phase 2Terminated
- Sponsor
- Roche
- Start
- Dec 2018
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of ralmitaront in schizophrenia, schizoaffective disorder, sponsored by Roche. Started Dec 2018; status: terminated.
02
Drugs
ralmitaront
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT03669640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03669640.